Surrozen, Inc./DE Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent
Surrozen, Inc./DE (SRZN) reported Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent of -1.07% for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Notes › Income Taxes
us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent · last filed 2026-03-23
- Surrozen, Inc./DE effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, percent for fiscal 2024 was -1.07%.
- Surrozen, Inc./DE effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, percent for fiscal 2023 was -1.74%, a 176.99% decline from fiscal 2022.
- Surrozen, Inc./DE effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, percent for fiscal 2022 was 2.26%.
- Surrozen, Inc./DE effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, percent for fiscal 2021 was 0.00%.
| Period end | Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent 12 month | Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent 12 month as first filed |
|---|---|---|
| 2024-12-31 | -1.07% 10-K · filed 2026-03-23 | |
| 2023-12-31 | -1.74% 10-K · filed 2025-03-31 | |
| 2022-12-31 | 2.26% 10-K · filed 2024-04-10 | -2.26% 10-K · filed 2023-03-31 |
| 2021-12-31 | 0.00% 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |